Medtronic에 대한 매도 수량은 투자자에게 Medtronic의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Medtronic (NYSE:MDT) 주식, 공매도 수량 보고

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

NVDA

TSLA

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 다소 개선되었음을 보여 주면서 화요일에는 &#34;중립&#34; 영역에 머물렀다.화요일(19일) 미국 증시는 혼조세를 보였으며, 나스닥 지수는 약 1% 상승했다. 이는 투자자들이 우크라이나와 러시아 간의 상승하는 지정학적 우려를 과소평가했기 때문이다.

엔비디아 실적 발표 앞두고 나스닥 1% 상승: 투자심리 개선, 공포·탐욕 지수는 &#39;중립&#39; 영역

화요일(19일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 종목은 다음과 같다. 월마트, 에이컴, 로우스, 심보틱 및 메드트로닉

화요일 주목해야 할 주식: 월마트, 에이컴, 로우스, 심보틱 및 메드트로닉

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 추가로 하락했음을 보여주었고, 월요일에 &#34;중립&#34; 영역에 머물렀다.월요일(18일) 미국 주식은 혼조세를 보인 가운데 나스닥 지수는 세션 중 100포인트 이상 상승했다. 이는 도널드 트럼프 대통령 당선자의 자율주행차 규제 완화 전망 보도에 따라 테슬라(NASDAQ:TSLA) 주식이 5.6% 급등하면서 나스닥도 오른 것이다. 

테슬라 오르면서 나스닥 100p 이상 상승: 투자심리 하락, 공포·탐욕 지수는 &#39;중립&#39; 영역에 머물러

Medtronic PLC

Measurable Data Token - United States dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MediaTek Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

Truist Securities analyst Richard Newitter maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Hold and lowers the price target from $93 to $89.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Medtronic, Lowers Price Target to $89

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$28.7K</td>
<td>19.8K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CADL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.00</td>
<td>$44.6K</td>
<td>1.2K</td>
<td>995</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$25.00</td>
<td>$28.7K</td>
<td>27.4K</td>
<td>566</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$75.00</td>
<td>$70.6K</td>
<td>95</td>
<td>286</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$10.00</td>
<td>$35.2K</td>
<td>5.8K</td>
<td>273</td>
</tr>
<tr>
<td>AMED</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$90.00</td>
<td>$147.5K</td>
<td>6.3K</td>
<td>250</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$580.00</td>
<td>$37.6K</td>
<td>1.0K</td>
<td>148</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$55.00</td>
<td>$26.5K</td>
<td>1.0K</td>
<td>130</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$270.00</td>
<td>$123.5K</td>
<td>217</td>
<td>48</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$105.00</td>
<td>$34.0K</td>
<td>32</td>
<td>32</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option sweep with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $15.00 strike. This particular call needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $287.0 per contract. There were 19843 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• Regarding CADL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>), we observe a call option sweep with bearish sentiment. It expires in 9 day(s) on December 20, 2024. Parties traded 372 contract(s) at a $6.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $44.6K, with a price of $120.0 per contract. There were 1230 open contracts at this strike prior to today, and today 995 contract(s) were bought and sold. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 401 day(s) on January 16, 2026. This event was a transfer of 101 contract(s) at a $25.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $285.0 per contract. There were 27415 open contracts at this strike prior to today, and today 566 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option sweep that happens to be bearish, expiring in 282 day(s) on September 19, 2025. This event was a transfer of 286 contract(s) at a $75.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $70.6K, with a price of $247.0 per contract. There were 95 open contracts at this strike prior to today, and today 286 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option trade with neutral sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 150 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $35.2K, with a price of $235.0 per contract. There were 5818 open contracts at this strike prior to today, and today 273 contract(s) were bought and sold. 
• Regarding AMED (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>), we observe a put option trade with bearish sentiment. It expires in 37 day(s) on January 17, 2025. Parties traded 250 contract(s) at a $90.00 strike. The total cost received by the writing party (or parties) was $147.5K, with a price of $590.0 per contract. There were 6378 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 37 day(s) on January 17, 2025. This event was a transfer of 8 contract(s) at a $580.00 strike. This particular put needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $4710.0 per contract. There were 1038 open contracts at this strike prior to today, and today 148 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 2 day(s) on December 13, 2024. This event was a transfer of 100 contract(s) at a $55.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $265.0 per contract. There were 1033 open contracts at this strike prior to today, and today 130 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bearish sentiment. It expires in 401 day(s) on January 16, 2026. Parties traded 47 contract(s) at a $270.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $123.5K, with a price of $2630.0 per contract. There were 217 open contracts at this strike prior to today, and today 48 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 44 day(s) on January 24, 2025. Parties traded 32 contract(s) at a $105.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $1065.0 per contract. There were 32 open contracts at this strike prior to today, and today 32 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMED

AMGN

CADL

RXRX

TEVA

10 Health Care Stocks Whale Activity In Today's Session

Looking into the current session, Medtronic Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) shares are trading at $85.62, after a 1.06% decrease. Over the past month, the stock fell by 4.53%, but over the past year, it actually increased by 8.32%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1733257847_0.png" alt="Past Year Chart" />

<h3>A Look at Medtronic P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 69.67 in the Health Care Equipment &amp; Supplies industry, Medtronic Inc. has a lower P/E ratio of 26.46. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1733257847_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Medtronic

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$86.00</td>
<td>$29.5K</td>
<td>72</td>
<td align="right">680</td>
</tr>
<tr>
<td>GEHC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/06/24</td>
<td>$84.00</td>
<td>$41.1K</td>
<td>24</td>
<td align="right">368</td>
</tr>
<tr>
<td>IBRX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$4.50</td>
<td>$25.0K</td>
<td>635</td>
<td align="right">330</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$720.00</td>
<td>$227.0K</td>
<td>99</td>
<td align="right">293</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$26.00</td>
<td>$94.8K</td>
<td>2.4K</td>
<td align="right">168</td>
</tr>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$75.00</td>
<td>$259.5K</td>
<td>533</td>
<td align="right">150</td>
</tr>
<tr>
<td>APLT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$33.0K</td>
<td>6.4K</td>
<td align="right">135</td>
</tr>
<tr>
<td>HROW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$31.9K</td>
<td>776</td>
<td align="right">118</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$240.00</td>
<td>$55.0K</td>
<td>491</td>
<td align="right">114</td>
</tr>
<tr>
<td>PSTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.00</td>
<td>$44.2K</td>
<td>85</td>
<td align="right">110</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we observe a put option sweep with bearish sentiment. It expires in 7 day(s) on December 6, 2024. Parties traded 674 contract(s) at a $86.00 strike. This particular put needed to be split into 44 different trades to become filled. The total cost received by the writing party (or parties) was $29.5K, with a price of $44.0 per contract. There were 72 open contracts at this strike prior to today, and today 680 contract(s) were bought and sold. 
• Regarding GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we observe a put option sweep with neutral sentiment. It expires in 7 day(s) on December 6, 2024. Parties traded 360 contract(s) at a $84.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $41.1K, with a price of $113.0 per contract. There were 24 open contracts at this strike prior to today, and today 368 contract(s) were bought and sold. 
• Regarding IBRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>), we observe a put option sweep with neutral sentiment. It expires in 168 day(s) on May 16, 2025. Parties traded 260 contract(s) at a $4.50 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $95.0 per contract. There were 635 open contracts at this strike prior to today, and today 330 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a put option trade with bullish sentiment. It expires in 112 day(s) on March 21, 2025. Parties traded 100 contract(s) at a $720.00 strike. The total cost received by the writing party (or parties) was $227.0K, with a price of $2270.0 per contract. There were 99 open contracts at this strike prior to today, and today 293 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option sweep that happens to be bearish, is expiring today. Parties traded 158 contract(s) at a $26.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $94.8K, with a price of $600.0 per contract. There were 2480 open contracts at this strike prior to today, and today 168 contract(s) were bought and sold. 
• Regarding BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we observe a call option sweep with bullish sentiment. It expires in 84 day(s) on February 21, 2025. Parties traded 150 contract(s) at a $75.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $259.5K, with a price of $1730.0 per contract. There were 533 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold. 
• Regarding APLT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>), we observe a put option trade with bearish sentiment. It expires in 49 day(s) on January 17, 2025. Parties traded 110 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $300.0 per contract. There were 6422 open contracts at this strike prior to today, and today 135 contract(s) were bought and sold. 
• For HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we notice a put option sweep that happens to be bullish, expiring in 413 day(s) on January 16, 2026. This event was a transfer of 19 contract(s) at a $50.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $31.9K, with a price of $1680.0 per contract. There were 776 open contracts at this strike prior to today, and today 118 contract(s) were bought and sold. 
• For DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we notice a call option trade that happens to be bearish, expiring in 21 day(s) on December 20, 2024. This event was a transfer of 110 contract(s) at a $240.00 strike. The total cost received by the writing party (or parties) was $55.0K, with a price of $500.0 per contract. There were 491 open contracts at this strike prior to today, and today 114 contract(s) were bought and sold. 
• For PSTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), we notice a call option trade that happens to be bullish, expiring in 49 day(s) on January 17, 2025. This event was a transfer of 100 contract(s) at a $5.00 strike. The total cost received by the writing party (or parties) was $44.2K, with a price of $442.0 per contract. There were 85 open contracts at this strike prior to today, and today 110 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLT

GEHC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HROW

IBRX

PSTX

10 Health Care Stocks With Whale Alerts In Today's Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Stifel raised the price target for Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) from $58 to $65. Stifel analyst Tore Svanberg maintained a Buy rating. Semtech shares closed at $53.44 on Monday. <a href="https://www.benzinga.com/quote/SMTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities raised the price target for Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) from $187 to $226. Truist Securities analyst Michael Ciarmoli reiterated a Buy rating. Woodward shares closed at $179.29 on Monday. <a href="https://www.benzinga.com/quote/WWD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays boosted Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) price target from $105 to $109. Barclays analyst Matt Miksic maintained an Overweight rating. Medtronic shares settled at $85.75 on Monday. <a href="https://www.benzinga.com/quote/MDT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo boosted Zoom Video Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) price target from $60 to $70. Wells Fargo analyst Michael Turrin maintained an Underweight rating. Zoom Video shares closed at $89.03 on Monday. <a href="https://www.benzinga.com/quote/ZM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised Health Catalyst, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) price target from $11 to $12. Piper Sandler analyst Jessica Tassan reiterated an Overweight rating. Health Catalyst shares closed at $8.52 on Monday.  <a href="https://www.benzinga.com/quote/HCAT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc boosted GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) price target from $62 to $74. Keybanc analyst Jason Celino maintained an Overweight rating on the stock. GitLab shares closed at $66.37 on Monday. See how other analysts view this stock.</li>
<li>Deutsche Bank cut the price target for Hubbell Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) from $493 to $473. Deutsche Bank analyst Nicole Deblase downgraded the stock from Buy to Hold. Hubbell shares settled at $463.86 on Monday. <a href="https://www.benzinga.com/quote/HUBB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HSBC boosted Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) price target from $128 to $131. HSBC analyst Saul Martinez downgraded the stock from Buy to Hold. Morgan Stanley shares closed at $133.66 on Monday. <a href="https://www.benzinga.com/quote/MS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo increased the price target for Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) from $100 to $115. Wells Fargo analyst Zachary Fadem maintained an Overweight rating. Starbucks shares closed at $101.84 on Monday. <a href="https://www.benzinga.com/quote/SBUX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler boosted The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) price target from $206 to $244. Piper Sandler analyst Paul Newsome maintained an Overweight rating. Allstate shares closed at $202.03 on Monday. <a href="https://www.benzinga.com/quote/ALL/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SBUX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-1024x583.png" alt="" class="wp-image-665498" style="width:659px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26090422/image-281.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

GTLB

HCAT

HUBB

SBUX

SMTC

Starbucks To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday

Barclays analyst Matt Miksic maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Overweight and raises the price target from $105 to $109.

Barclays Maintains Overweight on Medtronic, Raises Price Target to $109

<a href="https://www.medtronic.com/en-us/index.html">Medtronic plc</a>, a global leader in health care technology, announced today that the U.S. Department of Veterans Affairs (VA) has awarded a three-year Indefinite Delivery Indefinite Quantity (IDIQ) contract for <a href="https://www.medtronic.com/en-us/healthcare-professionals/products/digestive-gastrointestinal/gastrointestinal-artificial-intelligence/gi-genius-intelligent-endoscopy-module.html">GI Genius</a>&#x2122; AI-powered endoscopy units, resulting in almost 100 additional units being installed across VA medical centers nationwide. This expansion underscores the ability of Medtronic's proven technology to deliver state-of-the-art care to veterans, aiming to provide gold-standard diagnostic accuracy in colorectal screenings for thousands who served.

Contracts

Medtronic Awarded 3-Year VA Contract To Expand GI Genius AI Technology To Enhance Colorectal Cancer Detection In Veterans

Medtronic's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) short percent of float has fallen 4.76% since its last report. The company recently reported that it has 10.18 million shares sold short, which is 0.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Medtronic Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732302924_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Medtronic has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Medtronic's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Medtronic's peer group average for short interest as a percentage of float is 4.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Medtronic's Recent Short Interest

Bernstein analyst Lee Hambright maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and raises the price target from $96 to $97.

Bernstein Maintains Outperform on Medtronic, Raises Price Target to $97

Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Overweight and lowers the price target from $106 to $98.

Wells Fargo Maintains Overweight on Medtronic, Lowers Price Target to $98

New Smart MDI system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses.
GALWAY, Ireland, Nov. 20, 2024 /PRNewswire/ -- Medtronic&nbsp;plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new InPen&#x2122; app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera&#x2122; continuous glucose monitor (CGM). The company's Smart MDI system combines its InPen&#x2122; smart insulin pen with its newest Simplera&#x2122; CGM — the company's first disposable, all-in-one CGM that's half the size of previous Medtronic CGMs.
With this clearance, the system will be the first in the market to recommend corrections for missed or inaccurate insulin doses, providing real-time, personalized insights for individuals on multiple daily injection (MDI) therapy.&nbsp;

Biotech

General

Medtronic Receives FDA Clearance For New InPen App, Paving The Way For Its Smart MDI System Launch With Simplera CGM

Baird analyst David Rescott maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and lowers the price target from $96 to $93.

Baird Maintains Neutral on Medtronic, Lowers Price Target to $93

Needham analyst Mike Matson reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Medtronic

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Neutral&#8221; zone on Tuesday.
U.S. stocks settled mixed on Tuesday, with the Nasdaq gaining around 1% during the session as investors shrugged off rising geopolitical concerns between Ukraine and Russia. Ukraine launched its first U.S.-made missile strike on a Russian city, while Russian President Vladimir Putin adjusted the nation&#8217;s nuclear doctrine to broaden scenarios for a potential response.
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares gained around 5% on Tuesday ahead of its quarterly earnings report, due to be released today. Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares also gained 2%, adding around 38% month-to-date.
Shares of Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) rose around 3% on Tuesday after the company posted upbeat quarterly earnings and raised its outlook. Medtronic Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported better-than-expected results for its second quarter and raised its outlook.
On the economic data front, housing starts in the U.S. declined by 3.1% to 1.311 million in October versus a revised 1.353 million in the previous month. U.S. building permits declined by 0.6% to an annual rate of 1.416 million in October.
Most sectors on the S&amp;P 500 closed on a positive note, with energy, communication services, and consumer discretionary stocks recording the biggest gains on Monday. However, industrials stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed lower by around 121 points to 43,268.94 on Tuesday. The S&amp;P 500 rose 0.40% to 5,916.98, while the Nasdaq Composite gained 1.04% to close at 18,987.47 during Tuesday's session.
Investors are awaiting earnings results from Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>), The TJX Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>), and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 50.1, the index remained in the &#8220;Neutral&#8221; zone on Tuesday, versus a prior reading of 49.9.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:
<ul>
<li> <a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Nasdaq Gains 1% Ahead Of Nvidia Earnings: Investor Sentiment Improves, Fear & Greed Index Remains In 'Neutral' Zone

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday.
The Dow traded down 0.03% to 43,374.79 while the NASDAQ rose 1.03% to 18,985.21. The S&amp;P 500 also rose, gaining, 0.49% to 5,922.41.
Check This Out: <a href="https://www.benzinga.com/24/11/42059659/this-apollo-global-management-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday">This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday</a>
Leading and Lagging Sectors Information technology shares rose by 0.6% on Tuesday.
In trading on Tuesday, materials shares fell by 0.6%.
Top Headline
Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported better-than-expected results for its second quarter and raise its outlook.
The company posted second-quarter 2025 sales of $8.40 billion, beating the consensus of $8.27 billion. The medical device maker reported adjusted EPS of $1.26, beating the consensus of $1.25.
Medtronic raised its fiscal year 2025 organic revenue growth guidance to 4.75%-5%, up from the prior 4.5%-5%. If recent foreign currency exchange rates hold, 2025 revenue growth on an adjusted basis would be 3.4%-3.9%. Medtronic expects 2025 adjusted EPS guidance to be $5.44-$5.50 versus previous guidance of $5.42-$5.50 and consensus of $5.45.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares shot up 29% to $27.84 after the company announced the appointment of BDO USA as its independent auditor and the filing of a compliance plan with Nasdaq.</li>
<li>Shares of PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) got a boost, surging 172% to $1.4600. The company announced a 1-for-4 reverse stock split.</li>
<li>Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares were also up, gaining 30% to $3.30. The company, which makes specialty fitness equipment under the CLMBR and FORME brands, disclosed that Armah Sports Group‘s B_FIT is installing CLMBRs in three of its nine locations in Saudi Arabia.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares dropped 12% to $1.06. NWTN received Nasdaq staff delisting determination for non-compliance with Listing Rule 5250(c)(1).</li>
<li>Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) were down 13% to $66.74 after the company announced that data from its Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus does not support further development.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) was down, falling 11% to $6.77 after the company received a Nasdaq delisting notice due to its public reports rule.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $69.12 while gold traded up 0.7% at $2,632.40.
Silver traded up 0.3% to $31.305 on Tuesday, while copper rose 0.6% to $4.1435.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.45%, Germany's DAX fell 0.67% and France's CAC 40 fell 0.67%. Spain's IBEX 35 Index fell 0.74%, while London's FTSE 100 fell 0.13%.
Hourly labor costs in the Eurozone rose by 4.6% year-over-year in the third quarter compared to a revised 5% gain in the prior quarter. Annual inflation in the Eurozone rose to 2% in October from 1.7% in September.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.51%, Hong Kong's Hang Seng Index gaining 0.44%, China's Shanghai Composite Index gaining 0.67%&nbsp; and India's BSE Sensex gaining 0.31%.
Malaysia&#8217;s trade surplus narrowed to MYR 12.0 billion in October from MYR 13.0 billion in the year-ago month.
Economics
<ul>
<li>Housing starts in the U.S. declined by 3.1% to 1.311 million in October versus a revised 1.353 million in the previous month.</li>
<li>U.S. building permits declined by 0.6% to an annual rate of 1.416 million in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42060404/nvidia-to-rally-more-than-19-here-are-10-top-analyst-forecasts-for-tuesday-2">Nvidia To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Equities

Eurozone

Commodities

CDRO

INCY

NWTN

PRFX

SMCI

TRNR

Gold Moves Higher; Medtronic Posts Upbeat Results

Tuesday,&nbsp;Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported second-quarter 2025 sales of $8.40 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $8.27 billion</a>. The medical device maker reported adjusted EPS of $1.26, beating the consensus of $1.25.
Revenue increased 5.3% year over year, as reported,&nbsp;and 5% on an organic basis.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41184951/medtronic-recalls-minimed-pump-due-to-battery-life-concerns" rel="noreferrer noopener">Medtronic Recalls MiniMed Pump Due To Battery Life Concerns</a>
Cardiovascular segment revenue reached&nbsp;$3.102 billion, up 6.1% year over year as reported, and&nbsp;increased 5.6% organically, &nbsp;with a high-single-digit increase in Structural Heart &amp; Aortic and mid-single-digit increases in &nbsp;Cardiac Rhythm &amp; Heart Failure and Coronary &amp; Peripheral Vascular, all <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42058326/medtronic-reports-second-quarter-fiscal-2025-financial-results" rel="noreferrer noopener">on an organic basis</a>.
Neuroscience revenues of&nbsp;$2.45 billion&nbsp;increased 7.1% as reported and 6.7% organically, with a low-double-digit increase in Neuromodulation and mid-single-digit increases in Cranial &amp; Spinal Technologies and Specialty Therapies, all on an organic basis.
Medical Surgical&nbsp;revenue of&nbsp;$2.13 billion&nbsp;increased by 1.2% as reported and increased by 0.7% organically, with a low-single-digit organic increase in Acute Care &amp; Monitoring and flat organic result in Surgical &amp; Endoscopy.
Surgical &amp; Endoscopy year-over-year results were affected by a difficult comparison from the prior year supply recovery in Surgical and increased high-single digits sequentially.
Diabetes revenue of&nbsp;$686 million&nbsp;increased by 12.4%, as reported, and by 11% organic.
&#8220;Our momentum is building as we keep executing on our commitments, delivering yet another consecutive quarter of strong results that came in ahead of expectations,&#8221; said&nbsp;Geoff Martha, Medtronic chairman and chief executive officer.
Guidance:&nbsp;Medtronic raised its fiscal year 2025 organic revenue growth guidance to 4.75%-5%, up <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40462317/medical-devices-giant-medtronic-q1-earnings-revenue-and-eps-beat-lifts-annual-guidance-marginally-o" rel="noreferrer noopener">from the prior 4.5%-5%</a>.
If recent foreign currency exchange rates hold, 2025 revenue growth on an adjusted basis would be 3.4%-3.9%.
Medtronic expects 2025 adjusted EPS guidance to be $5.44-$5.50 versus previous guidance of $5.42-$5.50 and consensus of $5.45.
Price Action: MDT stock is down 3.52% at $84.53 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" target="_blank" rel="noreferrer noopener">Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination</a></li>
</ul>
Photo by Tony Webster via <a href="https://commons.wikimedia.org/wiki/File:Medtronic_Headquarters_Office_Building_-Mounds_View,_Minnesota(43381897454).jpg">Wikimedia Commons</a>

Large Cap

Guidance

Health Care

Movers

Medtronic Q2 Earnings: Diabetes And Neuroscience Revenue Boost Growth, Raises Annual Outlook

Medtronic shares are trading higher after the company reported better-than-expected Q2 adjusted EPS and sales and raised its FY25 guidance.

The company raised its FY25 diluted non-GAAP EPS guidance to the new range of $5.44 to $5.50 versus the prior $5.42 to $5.50. This includes an estimated -5% impact from foreign currency exchange based on recent rates, unchanged from the prior guidance. The company's guidance represents FY25 diluted non-GAAP EPS growth in the range of 4.6% to 5.8%.

Medtronic Raised Its Fy25 Adjusted EPS Guidance To $5.44-$5.50 Versus The Prior $5.42-$5.50 And Consensus Of $5.45

The company raised its FY25 organic revenue growth guidance to 4.75% to 5% versus the prior range of 4.5% to 5%. The organic revenue growth guidance excludes the impact of foreign currency and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, if recent foreign currency exchange rates hold, FY25 revenue growth on an adjusted basis would be in the range of 3.4% to 3.9%.

Medtronic Raised Its FY25 Organic Revenue Growth Guidance To 4.75%-5% Versus The Prior Range Of 4.5%-5%

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.25 by 0.8 percent. The company reported quarterly sales of $8.40 billion which beat the analyst consensus estimate of $8.27 billion by 1.59 percent. This is a 5.25 percent increase over sales of $7.98 billion the same period last year.

Medtronic Q2 2025 Adj EPS $1.26 Beats $1.25 Estimate, Sales $8.40B Beat $8.27B Estimate

The medtech market is thriving, thanks to the increasing investments and surging demand for enhanced efficiency. Therefore, investors could benefit from these trends by investing in fundamentally solid medical device stocks Becton, Dickinson and Company (BDX), Medtronic (MDT), and Abbott Laboratories (ABT), which are revolutionizing patient care. Keep reading... Patient care is changing globally due to the increasing aging population and the rising prevalence of chronic diseases, which results in higher demand for personalized medicine and the latest technologies. Following this, the global medtech market is continuously transforming with the rapid adoption of technological advancements like AI and ML.
Amid this backdrop, fundamentally sound medtech stocks Becton, Dickinson and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>), Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>), and Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>) could be ideal portfolio additions as they revolutionize patient care.
In recent times, technology has been a key driver of medical innovations, offering enhanced outcomes, lower costs, and improved access to better patient care. Also, amid the rising complications, global rise in diseases, and demand for personalized medicines, the involvement of technology is becoming more and more integral.
With this evolving landscape, industry leaders are pouring in investments to accelerate <a href="https://www.startus-insights.com/innovators-guide/medical-devices-market-report/#:~:text=In%202025%2C%20the%20medical%20devices,simulations%20will%20reshape%20healthcare%20delivery.">the adoption of innovative medical devices</a> to enhance diagnostics, treatment, and monitoring capabilities. In the upcoming year as well, key trends, including surgical robotics, 3D simulations, and brain-implanting technologies, will reshape patient care.
Statista projects the worldwide medical technology market to reach a staggering $597 billion in 2024, whereas the medical devices market is expected to dominate and reach $508 billion in 2024. The market is further anticipated to witness significant revenue growth in the coming years, <a href="https://www.statista.com/outlook/hmo/medical-technology/worldwide">growing at a CAGR of 5.3%</a>, resulting in a market volume of $772.50 billion by 2029.
Further, with advanced algorithms, machine learning techniques, and other technologies, artificial intelligence (AI) is enhancing the medical devices market. With this, <a href="https://www.thebusinessresearchcompany.com/report/ai-in-medical-devices-global-market-report">AI in the medical devices market</a> is expected to reach $97.07 billion in 2028, at a CAGR of 44.4%, driven by rising demand for personalized medicine, remote healthcare services, and the emergence of wearable devices.
Considering these conducive industry trends, let's analyze the fundamentals of the three <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> stocks mentioned above, beginning with the third choice.
Stock #3: Becton, Dickinson, and Company (<a href="https://stocknews.com/stock/BDX/">BDX</a>)
BDX develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public globally. It operates in three segments: BD Medical; BD Life Sciences; and BD Interventional.
On October 30, BDX launched the new BD&#xAE; Intraosseous Vascular Access System, which allows access to rapid delivery of fluids or medication in critical emergency circumstances. The procedure involves inserting a needle into the bone marrow cavity when intravenous (IV) access is challenging or delayed.
On October 14, BDX launched a new robotics solution that can automate and standardize single-cell research. This first in a family of high-throughput, robotics-compatible reagent kits allows automation to ensure higher consistency and increased efficiency of large-scale, single-cell discovery studies.
The automation will standardize traditionally manual processes and help accelerate lab work leading to Genomic sequencing.
During the fourth quarter that ended on September 30, 2024, BDX's revenues increased 6.9% year-over-year to $5.44 billion. Its <a href="https://www.investopedia.com/terms/o/operatingincome.asp">operating income</a> grew 86.4% from the year-ago value to $650 million. The company's net income applicable to common shareholders of $421 million indicates growth of 290.1% from the prior year's quarter.
In addition, the company's adjusted EPS from continuing operations came in at $3.81, up 11.4% year-over-year, respectively.
Analysts expect BDX's revenue for the first quarter (ending December 2024) to grow 8.8% year-over-year to $5.12 billion. The company's EPS is expected to increase 11.7% year-over-year to $2.99 for the ongoing period. Furthermore, the company surpassed the consensus EPS estimates in each of the trailing four quarters.
BDX's shares have declined 4.7% over the past month to close the last trading session at $223.01.
BDX's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Growth, Sentiment, and Stability. Within the <a href="https://stocknews.com/category/medical-devices-equipment/">Medical – Devices &amp; Equipment</a> industry, BDX is ranked #33 out of 138 stocks.
<a href="https://stocknews.com/stock/BDX/">Click here</a> to access additional BDX ratings for Value, Momentum, and Quality.
Stock #2: Medtronic plc (<a href="https://stocknews.com/stock/MDT/">MDT</a>)
MDT develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients globally. The company operates through Cardiovascular Portfolio; Neuroscience Portfolio; Medical Surgical Portfolio; and Diabetes Operating Unit segments.
On November 20, MDT announced U.S. FDA clearance for its new InPen&#x2122; app, having features like the detection of missed meal doses, paving the way for its Smart MDI system launch with the Simplera&#x2122; continuous glucose monitor (CGM). MDT's Smart MDI system brings together its InPen&#x2122; smart insulin pen and newest Simplera&#x2122; CGM.
After clearance, the system became the first to recommend corrections for missed or inaccurate insulin doses, providing real-time, personalized insights for individuals on multiple daily injection therapies.
Also, on November 1, MDT was granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral&#x2122; renal denervation (RDN) catheter by the Centers for Medicare &amp; Medicaid Services (CMS). RDN is used in the Symplicity&#x2122; blood pressure procedure under the Medicare Hospital Outpatient Prospective Payment System.
TPT payment supports patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.
MDT's net sales increased 5.2% year-over-year to $8.40 billion for the second quarter, which ended October 25, 2024. Its non-GAAP operating profit grew 1.6% from the year-ago value to $2.04 billion. Net income attributable to Medtronic and EPS came in at $1.27 billion and $0.99, up 39.7% and 45.6% from the prior year's quarter, respectively.
The company has again raised its fiscal year 2025 guidance from the prior range, increasing its organic revenue growth projection to 4.75% to 5%. It also raised its adjusted non-GAAP EPS guidance to $5.44 to $5.50 from the prior range of $5.42 to $5.50. This revised guidance suggests a 4.6% to 5.8% growth in non-GAAP EPS.
Street expects MDT's revenue for the third quarter (ending January 2025) to increase 3% year-over-year to $8.33 billion, and its EPS is expected to grow 4.6% year-over-year to $1.36 for the same period. Moreover, the company surpassed the consensus revenue and EPS estimates in all of the trailing four quarters, which is impressive.
MDT's stock has increased 1% over the past six months and 5.3% over the past year to close the last trading session at $83.96.
MDT's sound fundamentals are reflected in its POWR Ratings. It has an overall rating of B, translating to a Buy in our proprietary rating system.
The stock has a B grade for Stability and Value. Within the same industry, MDT is ranked #26 out of 138 stocks.
In addition to the POWR Ratings we've stated above, we also have MDT ratings for Growth, Momentum, Sentiment, and Quality. Get all MDT ratings <a href="https://stocknews.com/stock/MDT/">here</a>.
Stock #1: Abbott Laboratories (<a href="https://stocknews.com/stock/ABT/">ABT</a>)
ABT discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through four segments: Established Pharmaceutical Products; Diagnostic Products; Nutritional Products; and Medical Devices.
On October 10, ABT achieved new major milestones to support its pulsed field ablation (PFA) solutions suite in electrophysiology. ABT completed enrollment ahead of schedule in the global VOLT-AF IDE study supporting the Volt&#x2122; PFA System and launched the FOCALFLEX trial to assess its TactiFlex&#x2122; Duo Ablation Catheter, Sensor Enabled&#x2122; (SE) for treating paroxysmal atrial fibrillation.
Also, the company announced U.S. FDA clearance of its Advisor&#x2122; HD Grid X Mapping Catheter, Sensor Enabled&#x2122;, to support mapping of both PFA and radiofrequency (RF) ablation cases, where visualization of cardiac anatomy is critical. It ensures the best outcomes for people undergoing ablation procedures.
For the third quarter, which ended on September 30, 2024, ABT's net sales increased by 4.9% year-over-year to $10.64 billion. Its operating earnings of $1.86 billion reflect a growth of 12.8% from the prior year's quarter. Also, the company's adjusted net earnings stood at $2.12 billion or $1.21 per common share, indicating increases of 5.9% and 6.1% year-over-year, respectively.
Street expects ABT's revenue and EPS for the fourth quarter (ending December 2024) to increase 7.8% and 12.8% year-over-year to $11.04 billion and $1.34, respectively. Also, the company has topped the consensus EPS and revenue estimates in all four trailing quarters, which is remarkable.
Shares of ABT have surged 6.9% over the past six months and 8.2% over the past year to close the last trading session at $114.90.
ABT's POWR Ratings reflect its sound fundamentals. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
ABT has a B grade for Stability and Sentiment. It is ranked #13 out of 138 stocks in the Medical – Devices &amp; Equipment industry.
In addition to the POWR Ratings stated above, we also have ABT ratings for Quality, Growth, Momentum, and Value. Get all ABT ratings <a href="https://stocknews.com/stock/ABT/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
ABT shares were trading at $115.58 per share on Tuesday afternoon, up $0.68 (+0.59%). Year-to-date, ABT has gained 7.10%, versus a 28.26% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/abt-mdt-bdx-3-medtech-innovators-revolutionizing-patient-care/>3 MedTech Innovators Revolutionizing Patient Care</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 MedTech Innovators Revolutionizing Patient Care

Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends

Medtronic continues losses for seven straight sessions

American Century Equity Income Fund Q3 2024 Commentary

Truist lowered the firm's price target on Medtronic (MDT) to $89 from $93 and keeps a Hold rating on the shares as part of a broader research note ...

Medtronic price target lowered to $89 from $93 at Truist

My Dividend Stock Portfolio: New November Dividend Record - 97 Holdings With 18 Buys

Least shorted S&P 500 stocks in November

High-quality dividend growth stocks can build long-term wealth for shareholders. A major reason for this is the combination of dividend growth and dividend reinvestment.

10 Best Stocks For Compounding Dividends

Dividend Champion, Contender, And Challenger Highlights: Week Of December 22

AAPL

ABBV

AGNC

ALIZF

ALRS

AMCR

APLE

ARCC

AVGO

BABA

BASFY

BAYZF

BCPC

BXSL

CBAUF

CHRW

CSCO

CSWC

CUBE

CZFS

EPDU

FFMR

FMAO

FSNUF

FULT

GAIN

GILD

GLAD

GNTY

GOOD

GOOG

GSBD

GWRS

HASI

HLAN

HOFT

HTGC

INDB

INTC

INVH

KVUE

MAIN

MCHP

MFIC

MSFT

NDAQ

NEWT

NRIM

NWFL

OBDC

RBGLY

RBGPF

RITM

SEIC

SEMHF

SFBS

SHEL

SPTN

STAG

STWD

SWKS

THFF

TROW

TRUX

UNIT

XRAY

Screenshot 2024-10-03 at 5.30.47 PM

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Press Releases

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Medtronic reports second quarter fiscal 2025 financial results

Medtronic receives FDA clearance for new InPen™ app, paving the way for its Smart MDI system launch with Simplera™ CGM

Artificial Intelligence (AI) Reshaping Healthcare Industry with Unimaginable Potential

Comments

Medtronic

매도 수량

Medtronic (NYSE:MDT) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌